Abvc Biopharma (ABVC) Income from Continuing Operations (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Income from Continuing Operations came in at -$640280.0 in Q2 2026, up 72.55% on a YoY basis from -$371061.6 in Q2 2025, and up 52.04% quarter-over-quarter from -$1.3 million in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Income from Continuing Operations for 16 consecutive years, with -$640280.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations rose 72.55% year-over-year to -$640280.0; the trailing twelve-month figure through Jun 2026 stood at -$7.1 million (down 62.17% YoY), and the FY2025 full-year result was -$8.4 million, down 59.29% from the prior year.
- Income from Continuing Operations grew to -$640280.0 in Q2 2026 per ABVC's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at -$487431.0 in Q3 2024 and bottomed at -$6.1 million in Q1 2022.
- Historically, Income from Continuing Operations has averaged -$2.2 million across 5 years, with a median of -$2.0 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 409.29% in 2022, then soared 85.53% in 2024.
- Over 5 years, Income from Continuing Operations stood at -$4.5 million in 2022, then surged by 84.44% to -$700309.0 in 2023, then decreased by 13.74% to -$796527.0 in 2024, then slumped by 278.7% to -$3.0 million in 2025, then soared by 78.77% to -$640280.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered -$640280.0, -$1.3 million, and -$3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -640,280.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -640,280.00 |
| Mar 31, 2026 | -1.34 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.08 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -746,119.00 |
| Dec 31, 2024 | -796,527.00 |
| Sep 30, 2024 | -487,431.00 |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -700,309.00 |
| Sep 30, 2023 | -3.37 Mn |
| Jun 30, 2023 | -2.32 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | -4.50 Mn |
| Sep 30, 2022 | -3.78 Mn |
| Jun 30, 2022 | -1.95 Mn |
| Mar 31, 2022 | -6.09 Mn |
| Dec 31, 2021 | -6.90 Mn |
| Sep 30, 2021 | -1.89 Mn |